Quick answer
Tongren's team tested digital defocus vision training (DDVT) delivered through virtual reality: a VR headset generates controlled, dynamic myopic-defocus stimuli, aiming to slow eye growth in short-sighted children. In a randomised trial of 120 children aged 6–12, adding 15 minutes a day at home to single-vision glasses reduced 6-month axial elongation to 0.15 mm versus 0.25 mm with glasses alone — a 0.11 mm difference and a 0.23 D difference in refractive progression [1][3].
Key takeaways
- Conventional optical control (defocus spectacles, orthokeratology) uses fixed peripheral defocus, which cannot adapt to each child and gives limited stimulus [2].
- DDVT uses computer-vision algorithms and ray tracing to create individualised, dynamic defocus, upgraded from static optics to active digital intervention [1][2].
- In 120 children, 6-month axial growth was 0.15 mm with training versus 0.25 mm in controls; refractive progression was about halved [3][4].
- No serious adverse events were reported [4].
- The authors note the absolute effect is modest and short-term; it is better seen as a home adjunct than a standalone treatment [3].
The technology
Myopia control rests on the idea that peripheral myopic defocus slows eye growth. Spectacles and orthokeratology deliver a fixed optical signal; the Tongren team instead generates the defocus digitally, fusing four original technologies — image-processing aberration simulation, ray tracing to quantify defocus, VR intelligent defocus navigation, and gradient digital-defocus design — so the stimulus can be tailored and varied [1][2].
The system has been transferred to industry and received a Chinese Class II medical-device registration, so it exists as a regulated product, not only a research prototype [1][2].
What the trial found
The randomised trial enrolled 120 myopic children aged 6–12 and compared single-vision glasses plus 15 minutes of daily home VR training against glasses alone over six months. Axial length grew 0.15 mm versus 0.25 mm, and refraction progressed 0.23 D less — both statistically significant [3][4].
The authors themselves caution that 0.11 mm over six months is a small, short-term difference of uncertain clinical significance — similar in magnitude to defocus spectacles and far from what orthokeratology or atropine can achieve. Long-term data are needed before it can be recommended as a primary strategy [3].
The condition in context: childhood myopia
Myopia is rising rapidly in East Asia and is a leading public-health concern, with high and early-onset cases raising the risk of later eye disease.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | Myopia affects a large and growing share of children, especially in East Asia, and is a major cause of vision impairment [5]. | HealthDay / trial commentary [5] |
| Control options | Defocus spectacles, orthokeratology and atropine are established; each has limits on efficacy or adherence [2]. | Beijing government / Tongren [2] |
| China | Child and adolescent myopia is a national public-health priority, motivating home-based digital options [2]. | Beijing government [2] |
Because conventional options are fixed and often poorly adhered to, a home-based, individualised digital adjunct could fill a gap — if longer studies confirm its value [1][3].
Why it matters
| For the family | What the report suggests | Source |
|---|---|---|
| Convenience | A 15-minute daily home VR session is easy to fit into family life [2]. | [2] |
| Tailoring | Algorithm-driven defocus can adapt to each child, unlike fixed lenses [1]. | [1] |
| Caution | Effect is modest and short-term; it is an adjunct, not a replacement for proven control [3]. | [3] |
Availability and limits
- This is an editorial summary of journal and media reports, not an independent clinical assessment or a booking channel [1][2][3].
- The effect was measured over only six months; long-term efficacy is unproven [3].
- The magnitude (0.11 mm axial difference) is modest and similar to defocus spectacles [3].
- It is a regulated Class II device in China; availability and cost elsewhere vary [1].
- Myopia statements describe the condition generally and come from public-health sources, not this trial alone [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| How fast is my child's myopia progressing? | Treatment intensity should match progression rate and age [2]. |
| Should we use proven options (defocus lenses, orthokeratology, atropine) first? | DDVT's effect is modest; established options may be stronger [3]. |
| Which department handles foreign patients, and in what language? | Tongren is a working hospital we do not book; confirm international-department coordination and language support. |
| What follow-up and device support are needed? | Myopia control requires regular axial-length and refraction checks [1]. |
Questions patients ask
What is digital defocus vision training?
A VR-based approach that uses algorithms to generate individualised, dynamic myopic-defocus stimuli to slow eye growth in children, instead of fixed optical defocus from lenses [1][2].
What did the trial show?
In 120 children aged 6–12, 15 minutes a day of home VR training with glasses slowed 6-month axial growth to 0.15 mm versus 0.25 mm with glasses alone, with a 0.23 D difference in refractive progression [3][4].
How does it compare with other myopia control?
The 0.11 mm difference over six months is modest and similar to defocus spectacles, less than orthokeratology or atropine; it is best seen as an adjunct [3].
Is it safe?
No serious adverse events were reported in the trial, though longer-term safety data are needed [4].
Is this relevant to international patients considering eye care in China?
It is useful context for China's myopia-control innovation. Tongren is a working hospital we do not book — contact its international department directly and confirm candidacy, language support and travel logistics [1][2].